CASI Pharmaceuticals (NASDAQ:CASI) Issues Earnings Results

CASI Pharmaceuticals (NASDAQ:CASI) released its quarterly earnings results on Monday. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, Zacks reports. CASI Pharmaceuticals had a negative return on equity of 181.52% and a negative net margin of 143.18%.

CASI Pharmaceuticals Stock Performance

CASI traded down $0.08 during trading hours on Monday, hitting $2.13. 6,978 shares of the stock were exchanged, compared to its average volume of 83,227. CASI Pharmaceuticals has a 12 month low of $2.04 and a 12 month high of $7.67. The stock has a 50-day simple moving average of $2.39 and a 200-day simple moving average of $3.85. The company has a debt-to-equity ratio of 1.38, a current ratio of 3.20 and a quick ratio of 2.32. The stock has a market cap of $32.92 million, a price-to-earnings ratio of -0.95 and a beta of 0.41.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of CASI Pharmaceuticals in a research note on Thursday. They issued a “hold” rating for the company.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.